The total number of records retrieved from this search are 61. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5785	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 176.9 mm compared to control 278.1 after 53 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5786	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 598.8mm compared to control 755 after 63 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5787	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 668.4 mm compared to control 1169.9 after 69 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5788	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 896.6 mm compared to control 2512.7 after 77 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5789	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 298.8 after 41 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5790	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1448.3 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5791	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 2512.4 after 64 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5792	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 34.07 after 71 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5793	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 415.1 after 41 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5794	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1403.1 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5795	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1163.7 after 64 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5796	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 993 after 71 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5797	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 757.5 after 79 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5798	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 667 after 87 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5799	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 547 after 93 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5800	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 549 after 99 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5801	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 511 after 106 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5802	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 465.3 after 113 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5803	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 441.3 after 119 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5804	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 268.4 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5805	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 623.7 after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5806	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1232.5 after 70 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5807	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1277.05 after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5808	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1189.55 mm after 81 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5809	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 744.4mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5810	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 402.1 after 55 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5811	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1128.15 after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5812	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1485.05 after 70 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5813	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes to 1599.35 after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5814	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1411.4mm after 81 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5815	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1040mm after 89 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5816	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vector respectively	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (5mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for OVCAR-3 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 906.75 mm after 96 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5856	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for HT1080 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 11 mouse out of 12	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5857	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for PA-1 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 9 mouse out of 9	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5858	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for KB (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 7 mouse out of 12	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5859	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for SKMEL5 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 5 mouse out of 8	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5860	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 1 mouse out of 8	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5861	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for U87MG (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 1 mouse out of 9	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5862	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 2 out of 8 (tumor dimension 8 - 9.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5863	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration9.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 7 out of 8 (tumor dimension 8 - 9.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5864	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 3 out of 8 (tumor dimension 8 - 9.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5865	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 3 out of 3 (tumor dimension 10 - 11 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5866	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 3 out of 3 (tumor dimension 10 - 11 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5867	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in 3 out of 3 (tumor dimension 10 - 11 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5868	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 2 out of total 6 (tumor volume <300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5869	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration9.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 3 out of total 4 (tumor volume <300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5870	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 2 out of total 6 (tumor volume <300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5871	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 3 out of total 5 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5872	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration9.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 7 out of total 7 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5873	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+10 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 4 out of total 5 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5874	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor 7 out of 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5875	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor 6 out of 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5876	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor 5 out of 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5877	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor 5 out of 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5878	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume 7 out of 7 (Tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5879	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume 6 out of 7 (Tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5880	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume 4 out of 6 (Tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5881	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume 4 out of 6 (Tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5882	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing vasculostatin peptide	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for U87DeltaEGFR	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultSurvival time increased	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8450106
IDOV_5889	Virus nameRespiratory synctial virus	Virus strainMutant	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for PC-3 (3.0E+6), below ear	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 200mm after 38 days compared to control 1200mm	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMIDUS9241998
IDOV_5890	Virus nameRespiratory synctial virus	Virus strainMutant	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for PC-3 (3.0E+6), below ear	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 300mm after 35 days compared to control 900mm	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMIDUS9241998